The neurobiological basis of attention-deficit hyperactivity disorder (ADHD) in tuberous sclerosis complex is still largely unknown. Cortical tubers may disrupt several brain networks that control different types of attention. Frontal lobe dysfunction due to seizures or epileptiform electroencephalographic discharges may perturb the development of brain systems that underpin attentional and hyperactive functions during a critical early stage of brain maturation. Comorbidity of attention-deficit hyperactivity disorder (ADHD) with mental retardation and autism spectrum disorders is frequent in children with tuberous sclerosis. Attention-deficit hyperactivity disorder (ADHD) may also reflect a direct effect of the abnormal genetic program. Treatment of children with tuberous sclerosis complex with combined symptoms of attention-deficit hyperactivity disorder (ADHD) and epilepsy may represent a challenge for clinicians, because antiepileptic therapy and drugs used to treat attention-deficit hyperactivity disorder (ADHD) may aggravate the clinical picture of each other.
Curatolo P., Paloscia C., D’Agati E., Moavero R., Pasini A.The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol.2009;13(4):299-304.
2.
Valera EM, Faraone SV, Murray KE, Seidman LJMeta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1361-1369.
3.
Rubia K., Overmeyer S., Taylor E., et al. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. 1999;156(6): 891-896.
4.
Suskauer SJ, Simmonds DJ, Fotedar S., et al. Functional magnetic resonance imaging evidence for abnormalities in response selection in attention deficit hyperactivity disorder: differences in activation associated with response inhibition but not habitual motor response . J Cogn Neurosci. 2008;20(3):478-493.
5.
Curatolo P., Bombardieri R., Jozwiak S.Tuberous sclerosis. Lancet. 2008;372(9639):657-668.
6.
Napolioni V. , Moavero R., Curatolo P.Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev.2009;31(2): 104-113.
7.
de Vries PJ, Hunt A., Bolton PFThe psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry. 2007;16(1):16-24.
8.
Hunt A.Development, behaviour and seizures in 300 cases of tuberous sclerosis. J Intellect Disabil Res. 1993;37(pt 1):41-51.
9.
Gillberg IC, Gillberg C., Ahlsen G.Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev Med Child Neurol. 1994;36(1):50-56.
10.
Muzykewicz DA, Newberry P., Danforth N., Halpern EF, Thiele EAPsychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav. 2007;11:506-513.
11.
O’Callaghan FJ, Harris T., Joinson C., et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child. 2004;89(6):530-533.
12.
Dunn DW, Kronenberger WGChildhood epilepsy, attention problems, and ADHD: review and practical considerations . Semin Pediatr Neurol. 2005;12(4):222-228.
13.
Thome-Souza S., Kuczynski E., Assumpcao F. Jr, et al. Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy?Epilepsy Behav.2004;5(6):988-994.
14.
Prather P., de Vries PJBehavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol. 2004;19(9): 666-674.
15.
Curatolo P. , Cusmai R., Cortesi F., Chiron C., Jambaque I., Dulac O.Neuropsychiatric aspects of tuberous sclerosis . Ann N Y Acad Sci. 1991;615:8-16.
16.
Shepherd CW , Houser OW, Gomez MRMR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. AJNR Am J Neuroradiol. 1995;16(1): 149-155.
17.
Jansen FE, Vincken KL, Algra A., et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology. 2008;70(12):916-923.
18.
Aldenkamp AP , Arends J., Overweg-Plandsoen TC, et al. Acute cognitive effects of nonconvulsive difficult-to-detect epileptic seizures and epileptiform electroencephalographic discharges. J Child Neurol. 2001;16(2):119-123.
19.
Holtmann M. , Becker K., Kentner-Figura B., Schmidt MHIncreased frequency of rolandic spikes in ADHD children. Epilepsia. 2003;44(9):1241-1244.
20.
Semrud-Clikeman M., Wical B.Components of attention in children with complex partial seizures with and without ADHD. Epilepsia. 1999;40(2):211-215.
21.
Curatolo P. , Verdecchia M., Bombardieri R.Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol.2002;6(1):15-23.
22.
Powell AL, Yudd A., Zee P., Mandelbaum DEAttention deficit hyperactivity disorder associated with orbitofrontal epilepsy in a father and a son. Neuropsychiatry Neuropsychol Behav Neurol. 1997;10(2):151-154.
23.
McDonald CR , Delis DC, Norman MA, Wetter SR, Tecoma ES, Iragui VJResponse inhibition and set shifting in patients with frontal lobe epilepsy or temporal lobe epilepsy. Epilepsy Behav. 2005;7(3):438-446.
24.
Hernandez MT, Sauerwein HC, Jambaque I., et al. Attention, memory, and behavioral adjustment in children with frontal lobe epilepsy. Epilepsy Behav. 2003 ;4(5):522-536.
25.
Deonna T., Zesiger P., Davidoff V., Maeder M., Mayor C., Roulet E.Benign partial epilepsy of childhood: a longitudinal neuropsychological and EEG study of cognitive function. Dev Med Child Neurol. 2000;42(9):595-603.
26.
Ben-Ari Y. , Holmes GLEffects of seizures on developmental processes in the immature brain. Lancet Neurol.2006 ;5(12): 1055-1063.
27.
Joinson C., O’Callaghan FJ, Osborne JP, Martyn C., Harris T., Bolton PFLearning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complexPsychol Med. 2003;33(2):335-344.
28.
de Vries P., Watson P.Attention deficits in tuberous sclerosis complex (TSC): rethinking the pathways to the endstate. J Intellect Disabil Res. 2008;52(pt 4):348-357.
29.
Curatolo P. , Porfirio MC, Manzi B., Seri S.Autism in tuberous sclerosis. Eur J Paediatr Neurol.2004;8(6):327-332.
Hastings RP , Beck A., Daley D., Hill C.Symptoms of ADHD and their correlates in children with intellectual disabilities. Res Dev Disabil. 2005;26(5):456-468.
32.
Hunt A., Dennis J.Psychiatric disorder among children with tuberous sclerosis. Dev Med Child Neurol. 1987;29(2):190-198.
33.
Smalley SLAutism and tuberous sclerosis. J Autism Dev Disord.1998;28(5):407-414.
34.
Ogdie MN, Fisher SE, Yang M., et al. Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. Am J Hum Genet. 2004;75(4):661-668.
35.
Smalley SL, Kustanovich V., Minassian SL, et al. Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. Am J Hum Genet. 2002;71(4):959-963.
36.
Liu J., Nyholt DR, Magnussen P., et al. A genomewide screen for autism susceptibility loci. Am J Hum Genet. 2001;69(2): 327-340.
37.
Barnby G., Abbott A., Sykes N., et al. Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J Hum Genet. 2005;76(6):950-966.
38.
Turic D., Langley K., Mills S., et al. Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry. 2004;9(2):169-173.
39.
Adams J., Crosbie J., Wigg K., et al. Glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene as a positional candidate for attention-deficit/hyperactivity disorder in the 16p13 region. Mol Psychiatry. 2004;9(5):494-499.
40.
Dorval KM, Wigg KG, Crosbie J., et al. Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/ hyperactivity disorder. Genes Brain Behav . 2007;6(5):444-452.
41.
Adriani W., Canese R., Podo F., Laviola G.1H MRS-detectable metabolic brain changes and reduced impulsive behavior in adult rats exposed to methylphenidate during adolescence. Neurotoxicol Teratol. 2007;29(1):116-125.
42.
Carrey NJ, MacMaster FP, Gaudet L., Schmidt MHStriatal creatine and glutamate/glutamine in attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(1):11-17.
43.
de Vries PJ , Howe CJThe tuberous sclerosis complex proteins- a GRIPP on cognition and neurodevelopment. Trends Mol Med. 2007;13(8):319-326.
44.
Torres AR, Whitney J., Gonzalez-Heydrich J.Attention-deficit/ hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008;12(2): 217-233.
45.
Collins JJ, Tudor C., Leonard JM, Chuck G., Franz DNLevetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006;21(1):53-57.
46.
Wheless JW, Ng YTLevetiracetam in refractory pediatric epilepsy. J Child Neurol . 2002;17(6):413-415.
47.
Rugino TA, Samsock TCLevetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002;23(4):225-230.
48.
Uvebrant P. , Bauziene R.Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics. 1994;25(6):284-289.
49.
Schubert R.Attention deficit disorder and epilepsy. Pediatr Neurol. 2005;32(1):1-10.
50.
Baptista-Neto L., Dodds A., Rao S., Whitney J., Torres A., Gonzalez-Heydrich J.An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs.2008; 17(1):77-84.
51.
Feldman H., Crumrine P., Handen BL, Alvin R., Teodori J.Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child. 1989;143(9):1081-1086.
52.
Gross-Tsur V., Manor O., van der Meere J., Joseph A., Shalev RSEpilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?J Pediatr . 1997;130(4):670-674.
53.
Gucuyener K. , Erdemoglu AK, Senol S., Serdaroglu A., Soysal S., Kockar AIUse of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol.2003;18(2): 109-112.
54.
Hernandez A. , Barragan P.Efficacy of atomoxetine treatment in children with ADHD and epilepsy. Epilepsia. 2005; 46(suppl 6):718.
Wernicke JF , Holdridge KC, Jin L., et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol. 2007;49(7):498-502.
57.
Handen BL, Sahl R., Hardan AYGuanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29(4):303-308.
58.
Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MPClonidine for attention-deficit/ hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180-188.
de Vries P. , Humphrey A., McCartney D., et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in tuberous sclerosis . Eur Child Adolesc Psychiatry. 2005;14(4):183-190.
